Dopamine agonist-induced dyskinesias are correlated to both firing pattern and frequency alterations of pallidal neurones in the MPTP-treated monkey

Brain

Volumn 124, Issue 3, 2001, Pages 546-557

  Boraud, Thomas ^a   Bezard, Erwan ^a   Bioulac, Bernard ^a   Gross, Christian E ^a,b  

^a CNRS   (France)

^b UNIVERSITÉ DE BORDEAUX   (France)

Author keywords

Firing frequency; Globus pallidus; Parkinson's disease; Single unit recordings

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; 2,3,4,5 TETRAHYDRO 7,8 DIHYDROXY 1 PHENYL 1H 3 BENZAZEPINE; APOMORPHINE; DOPAMINE; DOPAMINE 1 RECEPTOR STIMULATING AGENT; DOPAMINE 2 RECEPTOR STIMULATING AGENT; DOPAMINE 3 RECEPTOR STIMULATING AGENT; DOPAMINE RECEPTOR STIMULATING AGENT; PIRIBEDIL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BEHAVIOR; CONTROLLED STUDY; DYSKINESIA; ELECTROPHYSIOLOGY; FEMALE; GLOBUS PALLIDUS; MONKEY; MOTOR DYSFUNCTION; NERVE CELL; NEUROPATHOLOGY; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; SINGLE UNIT ACTIVITY;

EID: 0035104574     PISSN: 00068950     EISSN: None     Source Type: Journal    
DOI: 10.1093/brain/124.3.546     Document Type: Article

References (47)

1. Functional architecture of basal ganglia circuits: Neural substrates of parallel processing
2. Pathophysiology of L-dopa-induced dyskinesias
3. Reversal of rigidity and improvement in motor performance by subthalamic high-frequency stimulation in MPTP-treated monkeys
4. Riluzole prevents MPTP-induced parkinsonism in the rhesus monkey: A pilot study
5. The primate subthalamic nucleus. II. Neuronal activity in the MPTP model of parkinsonism
6. Compensatory effects of glutamatergic inputs to the substantia nigra pars compacta in experimental parkinsonism
7. Involvement of the subthalamic nucleus in glutamatergic compensatory mechanisms
8. Is striatal dopaminergic receptor imbalance responsible for levodopa-induced dyskinesia?
9. Dyskinesia and wearing-off following dopamine D1 agonist treatment in drug-naive 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned primates
10. High frequency stimulation of the internal globus pallidus (GPi) simultaneously improves parkinsonian symptoms and reduces the firing frequency of GPi neurons in the MPTP-treated monkey
11. Effects of L-DOPA on neuronal activity of the globus pallidus externalis (GPe) and globus pallidus internalis (GPi) in the MPTP-treated monkey
12. Ratio of inhibited-to-activated pallidal neurons decreases dramatically during passive limb movement in the MPTP-treated monkey
13. Effects of riluzole on the electrophysiological activity of pallidal neurons in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated monkey
14. Nigrostriatal damage is required for induction of dyskinesias by L-DOPA in squirrel monkeys
15. Ultrastructural localization of D1 dopamine receptor immunoreactivity in rat striatonigral neurons and its relation with dopaminergic innervation
16. Primate models of movement disorders of basal ganglia origin
17. Treating and preventing levodopa-induced dyskinesias: Current and future strategies
18. Abnormal spontaneous activity of globus pallidus neurons in monkeys with MPTP-induced parkinsonism
19. Effects of dopamine agonists on the spontaneous activity of globus pallidus neurons in monkeys with MPTP-induced parkinsonism
20. 2 dopamine receptor-regulated gene expression of striatonigral and striatopallidal neurons
21. Effect of chronic treatment with (+)-PHNO, a D2 agonist in MPTP-treated monkeys
22. Dyskinesias and tolerance induced by chronic treatment with a D1 agonist administered in pulsatile or continuous mode do not correlate with changes of putaminal D1 receptors in drug-naive MPTP monkeys
23. Continuous or pulsatile chronic D2 dopamine receptor agonist (U91356A) treatment of drug-naive 4-phenyl-1,2,3,6-tetrahydropyridine monkeys differentially regulates brain D1 and D2 receptor expression: In situ hybridization histochemical analysis
24. High-frequency stimulation of the globus pallidus internalis in Parkinson's disease: A study of seven cases
25. Effects of intrasubthalamic injection of dopamine receptor agonists on subthalamic neurons in normal and 6-hydroxydopamine-lesioned rats: An electrophysiological and c-Fos study
26. Effects of apomorphine on globus pallidus neurons in parkinsonian patients
27. Comparison of eight clinical rating scales used for the assessment of MPTP-induced parkinsonism in the macaque monkey
28. The rationale for the use of dopamine agonists in Parkinson's disease
29. Burst and oscillation as disparate neuronal properties
30. Differential therapeutic effects of dopamine D1 and D2 agonists in MPTP-induced parkinsonian monkeys: Clinical implications
31. D1 and D2 dopamine receptor gene expression in the rat striatum: Sensitive cRNA probes demonstrate prominent segregation of D1 and D2 mRNAs in distinct neuronal populations of the dorsal and ventral striatum
32. Dopamine-adenosine interactions in the striatum and the globus pallidus: Inhibition of striatopallidal neurons through either D2 or A2A receptors enhances D1 receptor-mediated effects on c-fos expression
33. Differential distribution of D3 dopamine receptors in the brains of several mammalian species
34. Neuronal recordings in Parkinson's disease patients with dyskinesias induced by apomorphine
35. 2 receptor binding in the rat brain and pituitary: An in situ hybridization-receptor autoradiographic analysis
36. Fluctuations of disability in Parkinson's disease - Clinical aspects
37. Apomorphine induces changes in GPi spontaneous outflow in patients with Parkinson's disease
38. GPi firing rate modification during beginning-of-dose motor deterioration following acute administration of apomorphine
39. Neuronal activity in the primate premotor, supplementary, and precentral motor cortex during visually guided and internally determined sequential movements
40. Levodopa-induced dyskinesia: Review, observations, and speculations
41. Pathophysiology of levodopa-induced dyskinesias in Parkinson's disease: Problems with the current model
42. Internal globus pallidus discharge is nearly suppressed during levodopa-induced dyskinesias
43. An appraisal of the antiparkinsonian activity of piribedil in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated common marmosets
44. Novel dopamine receptors half a decade later
45. Effects of increasing doses of apomorphine during stereotaxic neurosurgery in Parkinson's disease: Clinical score and internal globus pallidus activity
46. Coordinated expression of dopamine receptors in neostriatal medium spiny neurons
47. Behavioral effects of MPTP administration in the vervet monkey, a primate model of Parkinson's disease